The Cancer Research of Kansas (CR Kansas) NCORP, formerly the Wichita Community Clinical Oncology (WCCOP), established and funded by the National Cancer Institute (NCI) in 1983, continued in 1987 (for 3 years), in 1990 (for 5 years), in 1995 (for 5 years), in 2000 (for 5 years), in 2005 (for 5 years), and 2010 (for 5 years). The WCCOP was a citywide cooperative program of the two major community hospitals and most of the Wichita oncologists. CR Kansas is a program, which will provide clinical trial access to a large portion ofthe state, including three community hospitals and most of the state's oncologists. Wichita is located n the center of the United States. It has the largest population center between Kansas City, 200 mile to the northeast, Denver, Colorado, 600 miles to the northwest, and Oklahoma City, 160 miles to the south. The presence of the CCOP/NCORP in Wichita brings the benefits of clinical research to patients in Wichita and its catchment area of south central, southwest and northeast Kansas - an ara that would otherwise be underserved because of its remote distance from the larger comprehensive cancer centers. CR Kansas consortium is in the process of developing a collaborative continuum of care that connects CR Kansas and community resources to deliver patient-centered, clinically integrated care for oncology patients, while demonstrating excellence in safety, quality and reducig avoidable costs. This collaboration will develop a coalition between practitioners across the stateof Kansas and Northern Oklahoma, including oncologists, primary care, surgeons, etc., that will provid an overall continuum of care from screening and prevention services through diagnosis, treatment an follow-up. CR Kansas aims to bring the state of Kansas community together in improving the overall f cancer care statewide. The CR Kansas National Community Oncology Research Program plans to continue an annual accrual of 200 credits on treatment protocols and 400 new credits on cancer control protocols using the eight research bases: NRG, SWOG, ECOG-ACRIN, Alliance, Wake Forest, University of Rochester, M.D. Anderson CCOP, SunCoast, as well as the Cancer Trials Support Unit.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Whitman, Cynthia B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Via Christi Regional Medical Center
United States
Zip Code
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Wagner, Lynne I; Zhao, Fengmin; Goss, Paul E et al. (2018) Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG Breast Cancer Res Treat 169:537-548
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703

Showing the most recent 10 out of 40 publications